Vijay Chudasama Works In the Hottest Biotechnology Areas

With the brilliant brains of Vijay Chudasama, working on one of the hottest biotechnology drugs is easy. Chudasama, the co-founder and technical director of ThioLogics from September 2013 to present, leads the company in the research and development of a revolutionary sites-specific conjugation platform across several sectors.

The technology will allow the effective and efficient combination of antibodies, the body’s system for identifying and destroying possibly toxic organisms or cells, with other drugs including medicines. This will provide doctors with the opportunity to deliver chemotherapy drugs to tumour cells only, thus, lessening the side effects, among other applications.

Chudasama also worked as an intellectual property consultant for ThioLogics from August 2012 to present. He is credited for ThioLogic’s efficacy in relation to patent prosecution, claim construction, and application strategy, among others.

ThioLogics, a biotechnology company, was established by Dr. Vijay Chudasama together with Dr. James Baker and Professor Stephen Caddick. The company was founded based on the proprietary chemistries developed by the co-founders at the University College London laboratories. The conjugation platform allows for the stable, selective and functional modification of free cysteine or disulfide bonds in proteins, peptides and antibodies – truly, a revolutionary invention in its own right.

He has published 20 – and counting – peer-reviewed publications as well as granted with a patent, namely, the Thiol Protecting Group (Europe EP2464654) issued 9 August 2010. The patent is useful in the creation of functional conjugate compounds, among other functions.

Chudasama possesses several other professional credentials. He worked as a trainee patent attorney at JA Kemp where he gained extensive experience in patent processes; as a tutorial and laboratory instructor at New York University London where his teaching skills were honed; and as process chemist at AstraZeneca and a medicinal chemist at Arrow Therapeutics where his chemist skills became advanced, among others.